A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head & Neck Squamous Cell Carcinoma
Primary Sponsor
EORTC
Collaborating Groups
TROG Cancer Research
Related Post
8 July, 2025
Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial
TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE
26 June, 2025
Cancer Survivor to Take on Fifth Kokoda trek to Support TROG
LATEST NEWS: 26 June 2025 He may be 76
